As a result of neuro-vascular coupling, the functional effects of antipsychotics in human brain have been investigated in both healthy and clinical populations using haemodynamic markers such as regional Cerebral Blood Flow (rCBF). However, the relationship between observed haemodynamic effects and the pharmacological action of these drugs has not been fully established. Here, we analysed Arterial Spin Labelling (ASL) rCBF data from a placebo-controlled study in healthy volunteers, who received a single dose of three different D2 receptor (D 2 R) antagonists and tested the association of the main effects of the drugs on rCBF against normative population maps of D 2 R protein density and gene-expression data. In particular, we correlated CBF changes after antipsychotic administration with non-displaceable binding potential (BP ND 
Introduction
Antipsychotics are still the preferred choice for the treatment of conditions such as schizophrenia and other mental health disorders with psychotic features (Stroup et al., 2009) . The main target of most of these compounds is the dopamine D 2 receptor (D 2 R) (Burt et al., 1977; Farde et al., 1986) where they act as antagonists or partial agonists. D 2 R occupancy of antipsychotics has been assessed in vivo with emission tomography in healthy controls and clinical populations (Agid et al., 2007; Kapur et al., 1995; Nyberg et al., 1995) and it has also been linked with treatment response (Kapur et al., 2000) . While antipsychotics have been well characterized in terms of their pharmacokinetics (PK) and clinical response, their impact on brain physiology and function is still not well understood. A deeper understanding of these effects is crucial to uncover biological mechanisms driving their clinical efficacy as well as their side effects.
Functional effects of antipsychotics in the brain have been investigated using different neuroimaging tools. Seminal work using Positron Emission Tomography (PET) [ showed that drug naïve first episode psychosis patients, had increased glucose utilization after treatment with antipsychotics (DeLisi et al., 1985; Holcomb et al., 1996) and greater perfusion (Goozee et al., 2014; Miller et al., 2001 Miller et al., , 1997 in the basal ganglia. Similar results were also obtained in healthy volunteers using a single dose of antipsychotics (Kim et al., 2013; Mehta, 2003) . Studies using Arterial Spin Labelling (ASL), a Magnetic Resonance Imaging (MRI) sequence designed to quantitatively measure regional cerebral blood flow (rCBF), found results in line with the earlier PET studies. In particular (Fern andez-Seara et al., 2011) , reported increased rCBF in the striatum and thalamus in healthy volunteers after a single oral dose of 10 mg of metoclopramide (a D 2 R antagonist) and (Handley et al., 2013) showed that both haloperidol 3 mg (a D 2 R antagonist) and aripiprazole 10 mg (a D 2 R partial agonist with 5-HT2a antagonism properties) increased rCBF in the striatum in healthy volunteers with a larger effect size for haloperidol. Recently, we tested the effects of a single clinical effective dose of different antipsychotics . Consistent with the existing literature, 3 mg haloperidol, 2 mg risperidone and 0.5 mg risperidone increased striatal rCBF as compared with placebo.
One of the major limitations of pharmacological MRI studies stands on the haemodynamic nature of the main functional measures (e.g. BOLD and rCBF). According to the neurovascular coupling model (Attwell and Iadecola, 2002; Logothetis et al., 2001 ) changes in haemodynamic MRI measures reflect a complex cascade of cellular, metabolic and vascular events associated with changes in neuronal activity (Heeger and Ress, 2002; Hoge et al., 1999; Singh, 2012) . In line with this model, the main effects of drug may be interpreted as the result of dose-dependent enhanced or reduced pre-or post-synaptic activity due to the action of the drug on its targets (Khalili-Mahani et al., 2017) . Although many antipsychotics bind to numerous receptors, the effects on rCBF have been tacitly attributed to D 2 R blockade. In particular, D 2 R antagonism would lead to enhanced neurotransmitter turnover in the dopaminergic synapses inducing metabolic activity and therefore perfusion demands (Goozee et al., 2014; Handley et al., 2013) . The findings of altered dopamine synthesis capacity after acute antipsychotics administration in human volunteers and rats support this hypothesis (Hertel et al., 1996; Ito et al., 2009; Vernaleken et al., 2008) . However, since MRI does not measure neuronal activity directly, making a link between neuro-receptor binding and haemodynamic effects of these compounds requires a degree of conjecture. In addition, in the case of dopaminergic drugs, MRI hemodynamic changes have also been related to non-neuronal mechanisms including the action of D 1 -like receptors on vessels and D 2 -like receptors (mainly D 3 R) on perivascular astrocytes and endothelial cells (Choi et al., 2006; Krimer et al., 1998) . For these reasons, despite the body of evidence, the neurochemical mechanisms underlying CBF changes after antipsychotics administration remain unclear. The use of multimodal approaches, e.g. combining MR measures with ex-vivo autoradiography , have started to fill this gap of knowledge.
Receptor occupancy theory posits that the magnitude of the drug response is a function of receptor availability (Clark, 1970; Ploeger et al., 2009) . In other words, incremental changes in functional response correspond to increments of the fraction of receptors bound. This relationship also depends on specific characteristics of each compound, such as receptor affinity (i.e. K i ). This basic pharmacology principle has been used to characterize the spatial profile of drug effects in the brain (also called "drug fingerprinting") assuming that brain regions with high density of the target receptor will show higher magnitude of drug effects (Khalili-Mahani et al., 2017) . This approach has been proposed to describe MRI changes to dopaminergic drugs in preclinical data . Indeed, a monotonic increase in regional Cerebral Blood Volume (rCBV) has been observed following injection of an increasing dose of the D 2 /D 3 antagonist radiotracer [ 11 C]raclopride in the striatum of two male rhesus macaques . Interestingly, [
11 C]raclopride non-displaceable binding potential changes (BP ND ) reflecting changes in D 2 /D 3 receptor occupancy, correlated with the amplitude of hemodynamic changes (i.e. rCBV): the higher the dose the larger rCBV increase; and in time: BP ND variation and changes in rCBV showed similar temporal profiles. The same group also found an inverse relationship between receptor occupancy and rCBV with the selective D 2 /D 3 agonist quinpirole in male rhesus macaques (i.e. rCBV decrease in face of dose-dependent increase of receptor occupancy) (Sander et al., 2016) . Both studies provide evidence for a neurovascular coupling mechanism linking MR haemodynamic changes and D 2 /D 3 receptors pharmacological modulation in non-human primates although they are limited to the striatal region. The aim of the present work is to test in humans whether rCBF changes induced by a single dose of different antipsychotics co-varies with in vivo measures of D 2 R distribution. In particular, we employed two datasets from healthy volunteers to evaluate the spatial correlation between rCBF variation in the placebo vs antipsychotic comparison against the population-based receptor density profiles derived from human PET scans using the high affinity D 2 /D 3 antagonist [ 18 F]Fallypride (Mukherjee et al., 1995) . We also investigated the same relationship at the gene expression level using post-mortem mRNA expression measures of the DRD2 gene (the gene coding for D 2 R) extracted from the Human Allen Brain Atlas (ABA) (Hawrylycz et al., 2012) . Brain mRNA expression variation across brain regions has been shown to be associated with resting state fMRI networks suggesting that brain hemodynamic response may be linked to the architecture of the human brain transcriptome (Hawrylycz et al., 2015; Richiardi et al., 2015) . Here, brain microarray mRNA expression data was chosen as a proxy to protein-level receptor density in the human brain. In fact, while post-transcriptional events may alter the relationship between gene expression and protein synthesis (Liu et al., 2016 ), brain mRNA expression maps have been shown to predict in vivo proteins level as measured with PET (Beliveau et al., 2017; Rizzo et al., 2014) .
Following the receptor occupancy theory and the neurovascular coupling model proposed by we hypothesized that there will be a detectable linear relationship between main effects of antipsychotics on CBF measures and D 2 R receptor density profiles evaluated at the protein and gene expression level. Even though brain microarray mRNA expression data from the ABA is noisier and more discrete (i.e. limited number of samples) than the PET BP ND maps, we expect CBF increases after antipsychotics to be linearly associated also with DRD2 mRNA expression spatial profiles. However, given the fact that mRNA expression only approximates cellular protein levels due to post-transcriptional regulatory mechanisms we predict microarray data to explain less variance in CBF changes than PET derived maps.
Materials and methods

Participants and study design
Data were collected as part of a project approved by the National Research Ethics Service Committee London -Brent (REC reference: 13/ LO/1183). Details about participants, protocol and study design have been described in detail in . Briefly, forty-two healthy male subjects were enrolled in a double-blind, placebo-controlled, randomised, fully counterbalanced, three-session crossover design. Participants were randomised into two equal parallel study groups (Group 1 age mean/SD 27.6/6.9; Group 2 age mean/SD 28.3/6.3). In the first group participants received placebo, 7.5 mg of olanzapine (OLA), or 3 mg of haloperidol (HAL) on each study day. In the second group, participants received placebo, 0.5 or 2 mg risperidone (lowRIS and highRIS respectively). All but lowRIS dosage were chosen in order to achieve on average at least 60% of D2 receptor occupancy (Kapur et al., 2000; Tauscher et al., 2004) . On dosing day, participants followed a standardised regime. The MRI scan was performed at the time of predicted peak level of plasma concentration of the drug after oral administration (T max ): approximately 5 h after drug administration for Group 1 and 2 h for Group 2 (de Greef et al., 2011; Midha et al., 1989; Nyberg et al., 1995; Tauscher et al., 2004) . Study days were seven days apart to allow washout between sessions. After the final visit, a follow-up phone call was made to monitor potential adverse events related to the study drugs.
MRI acquisition and pre-processing
All scans were conducted on a GE MR750 3 Tesla scanner using a 12-channel head coil. ASL image data were acquired using a 3D pseudocontinuous ASL sequence (3DpCASL) with a multi-shot, segmented 3D stack of axial spirals (8-arms) readout with a resultant spatial resolution (after re-gridding and Fourier Transformation) of 2 Â 2 Â 3mm. Four control-label pairs were used to derive a perfusion weighted difference image. The labelling RF pulse had a duration of 1.5s and a post-labelling delay of 1.5s. The sequence included background suppression for optimum reduction of the static tissue signal. A proton density image was acquired in 48s using the same acquisition parameters in order to compute the CBF map in standard physiological units (ml blood/100 g tissue/min). Pre-processing of all CBF data was performed exactly as described in ) (for further details please see Supplementary Materials). (Dunn et al., 2009 (Desikan et al., 2006) and for each of the 85 Regions of Interest (ROIs) of the template, the voxel-wise mean BP ND value was extracted with the flslmeants function implemented in the Functional Software Library suite (FSL, FMRIB, Oxford, UK). Conventional parametric modelling of regional BP ND was performed by using the cerebellum as reference region (Ichise et al., 2003) . Therefore, both left and right cerebellar ROIs (namely "rh_cerebellum_cortex" and "lh_cer-ebellum_cortex") were excluded from correlation analyses with CBF profiles. To compare the contribution of striatal vs extra-striatal regions to this association, we also extracted BP ND profiles from a [ 11 C]raclopride template obtained from a matchted group of healthy controls (Grecchi et al., 2014 ) (see Supplementary Material).
Receptor density profiles
CBF profiles
CBF profiles were obtained from maps of CBF changes at the group level. In particular, for each antipsychotic, a group-wide paired T-test was performed in SPM12 for each drug vs placebo. Whole brain total blood flow was added as a covariate of no interest in the model to account for peripheral (global) drug effects and between-subjects variability in global brain perfusion (Handley et al., 2013; Viviani et al., 2013 Viviani et al., , 2009 ).
For each antipsychotic the main effect of the drug was tested using group voxel-wise paired t-tests with cluster-level FWE correction (alpha ¼ 0.05, cluster defining threshold ¼ 0.001) as implemented in SPM12. In agreement with previous studies (Handley et al., 2013; Hawkins et al., 2018) , we identified statistically significant increases in CBF after drug administration (against placebo) and have thus focussed on this contrast in the remainder of this work. Therefore, DRUG>PLACEBO contrast maps for each antipsychotic where segmented by using the Desikan-Killiany Atlas (Desikan et al., 2006) using the same approach used for the extraction of receptor profiles. This resulted in 85 ΔCBF profiles measuring the antipsychotic induced increase of CBF in each ROI. For consistency with the receptor profile data, we carried out correlation analyses excluding the two cerebellum ROIs.
Statistical analysis for the ΔCBF/receptor density profiles correlations
To test the associations between ΔCBF profiles (derived for each antipsychotic) and D 2 /D 3 receptor density profiles, linear regression models as implemented in SPSS were used (IBM, SPSS Statistics, Version 23). Normal distribution of the residuals of the regression models were tested by Shapiro-Wilk test. BP ND data were transformed using a natural logarithmic function (ln) so that the residuals conformed to a normal distribution. For all linear regression models Mahalanobis distance and Cook's distance were computed in order to explore the presence of multivariate outliers and estimate the presence of highly influential data points. To identify multivariate outliers, Mahalanobis distance values were compared to a chi-square distribution with degrees of freedom equal to the number of variables (two in this case) with p ¼ 0.001 (Finch, 2012; Tabachnick and Fidell, 2013) . Any data point with Cook's distance higher than 1 was considered as highly influential outlier and excluded from the analysis (Cook and Weisberg, 1982) . To further control for the effect of extreme observation we also used the bias-corrected accelerated bootstrap technique as implemented in SPSS (Efron and Tibshirani, 1986 ) with 10,000 resamples. Non-parametric Spearman's correlations between ΔCBF profiles and receptor BP ND profiles were also performed as a countercheck. In addition, Fisher's r-to-z transformation was performed to test pairwise significance of the difference between correlation coefficients of ΔCBF profiles between different antipsychotics. Asymptotic covariance method was adopted to account for the fact that correlations had one variable in common (Lee and Preacher, 2013 ).
2.6. mRNA profiles and genetic correlations DRD2 gene brain microarray mRNA expression values were extracted from ABA data (http://human.brain-map.org) by using the Multimodal Environment for Neuroimaging and Genomic Analysis (MENGA) toolbox (http://www.nitrc.org/projects/menga/) . The same toolbox was used to carry out correlations with ΔCBF profiles of each antipsychotic. First, antipsychotics' contrast images (DRUG>PLACEBO) were resampled in the ABA space. Then, each CBF image sample was spatially matched with the corresponding genomic ABA sample within a search window of a sphere of 5 mm radius centred on the MNI coordinates of the ABA sample. Both CBF contrast image and ABA data were then segmented using the list of structures (N ¼ 169) provided by the ABA (Hawrylycz et al., 2012) . A subset of 89 structures (ROIs), each containing at least one genomic sample for all the six ABA brains (donors), was selected to perform correlations between ΔCBF profiles and gene expression. For each donor, samples data were converted from their original log2 intensity in z-scores using mean and standard deviation as normalization factor for a given subject. This was done to minimize bias related to inter-donor variability in the ABA dataset. For the DRD2 gene a unique profile was obtained by selecting the probe which expression values were highly consistent across donors. In particular, distributions of expression values for all the probes were evaluated across donors, retaining the probe with the most symmetric and least skewed distribution. In the case of multiple samples within the same ROI, the average Fallypride PET template were segmented into 83 ROIs by using the Desikan-Killiany Atlas (Desikan et al., 2006) . For each ROI ΔCBF profiles and [18F]Fallypride BP ND template values were extracted and then correlated. DRD2 gene brain microarray mRNA expression values were extracted from ABA data (http://human.brain-map. org) (Hawrylycz et al., 2012) . MENGA software (http://www.nitrc.org/projects/menga/) was used to extract DRD2 mRNA expression profiles which then entered multivariate correlation analysis against ΔCBF profiles (please refer to Material and methods and Supplementary Material for a more detailed description).
between samples within the ROI was calculated .
After completing the matching and the extraction of ΔCBF and gene expression profiles, two different correlations were performed: 1) between-donors correlation or gene auto-correlation returning the biological variability of the spatial profile of mRNA expression between donors (the higher the gene autocorrelation the lower the heterogeneity in mRNA expression spatial profile between donors); 2) correlation between each gene expression and the ΔCBF by ROIs also called crosscorrelation. A Principal Component Analysis (PCA) on mRNA expression measures of the 6 ABA donors was performed beforehand in order to extract the component that accounted at least for the 95% of the total variance in the mRNA expression data. In particular, the PCA was performed on an 89 Â 6 matrix (89 ROIs by 6 donors) and represented a consistent spatial mRNA expression profile across all donors. This component was then used in the regression model against CBF profiles. Significance was assessed with a bootstrapping approach resulting in a chance likelihood of the correlation coefficient expressed as a %. More specifically, ROIs were permuted within donors repeating the correlation between PCA component and CBF profiles 1000 times, in order to obtain a measure of the likelihood that the correlation found was different from chance level. For further details on ABA mRNA processing and analysis see Supplementary Material and . A multivariate spatial correlation using MENGA was also performed between DRD2 gene expression profiles and [ 18 F]Fallypride BP ND maps (see Supplementary Material). As for protein density profile analysis, Fisher's r-to-z transformation was performed to test pairwise significance of the difference between correlation coefficients of ΔCBF profiles between different antipsychotics and also between PET and mRNA profiles.
Results
Main effect of antipsychotic on CBF
Group paired T-tests revealed that all antipsychotics but olanzapine, produced a statistically significant increase of CBF in basal ganglia, in particular in the striatum with haloperidol causing the largest increase as compared with lowRIS and highRIS. In particular HAL>PLA t-contrast revealed a significant cluster in the left Putamen; OLA>PLA t-contrast revealed a significant cluster in the righ parietal cortex and in the right parahippocampus; lowRIS>PLA t-contrast revealed a significant cluster in the left caudate; highRIS>PLA t-contrast revealed a significant cluster in the left caudate. None of the DRUG<PLA t-contrast revealed statistically significant clusters. Full statistics and voxel-wise t-maps are in Supplementary Material. 
CBF changes with D 2 receptor profiles correlations
mRNA expression correlations
The average correlation coefficient (R 2 ) of the genomic autocorrelation analysis for the DRD2 gene was 0.575 (standard deviation ¼ 0.058) for the six donors. This result indicated good stability between donors of DRD2 mRNA expression spatial profile .
For the different antipsychotic drugs, the correlation coefficients were all positive and statistically significant ( Fig. 3 (McCormick et al., 2010 ) between antipsychotics at D 2 R (Fig. 4) . However, none of the pairwise comparisons between correlation coefficients between antipsychotics were statistically significant after correction for multiple comparisons.
Discussion
The aim of the present study was to investigate the relationship between the effects of single clinical effective doses of antipsychotics on rCBF and receptor distribution profiles in the brain as indexed by [
18 F]
Fallypride BP ND values extracted from a template map and brain DRD2 mRNA expression profiles. Consistently with our hypothesis, we found that for all compounds there was a spatial coupling between druginduced CBF changes and D 2 receptor density profiles (at both protein and gene expression level). In addition, we found that mRNA data explained less variance in CBF changes than PET derived map.
Receptor density profiles
The association between CBF changes induced by all antipsychotics and receptor brain spatial distribution of D 2 R matches earlier evidence in non-human primates showing large CBF increases after injection of the D 2 antagonist PET tracer [
11 C]raclopride in brain regions with high D 2 R density . This suggests that the relationship between the physiological response to D 2 R antagonist and D 2 R availability described by in preclinical models also exists in vivo in humans. Furthermore, we have shown that the relationship between ASL-CBF increases after antipsychotic administration also matched [ 18 F] Sander et al. (2016; the functional measure was rCBV instead of rCBF. However, given the tight association between rCBV changes and rCBF changes (Ito et al., 2005) , we believe this difference will not affect the interpretation of our findings.
Microarray mRNA expression data
We found that for all antipsychotics, the ΔCBF profiles also correlated with microarray mRNA expression data extracted from the ABA. All genomic correlations were positive and therefore in the same direction of [ mechanisms (Liu et al., 2016) . Our findings are consistent with previous works that have linked the spatial architecture of the brain transcriptome to brain structure (Grecchi et al., 2017; Veronese et al., 2015) , function (Hawrylycz et al., 2015; Richiardi et al., 2015) and in vivo measures of brain proteins (Gryglewski et al., 2018; Rizzo et al., 2016 Rizzo et al., , 2014 Veronese et al., 2016) . Here we could show that post mortem brain mRNA expression data may potentially be used to map also variations in MRI functional response to drug stimulation. However, such mapping has still many limitations to be addressed in order to adopt it extensively in the context of pharmacological-MRI studies. For instance, it might be difficult to use mRNA expression mapping in neurotransmitter systems where protein synthesis is highly dependent on post-transcriptional regulation mechanisms (e.g. serotonin system) (Beliveau et al., 2017; Rizzo et al., 2014) . While further studies are needed to fully validate this mRNA expression-MRI approach, it might be especially valuable for profiling the functional effects of drugs with poorly characterized or unknown targets. Interestingly, as for the correlation with receptor density profiles, the rank order of correlations between ΔCBF and DRD2 mRNA expression measures mirrored affinity profiles of the compounds, although these differences were only numerical. It is worth noting that the variance explained by genomic correlation was lower than the PET correlations (Table 1) , which might have reduced the chance of detecting any significant difference on the pairwise comparison between the correlation coefficients. These findings represent a further evidence supporting the hypothesized PK/PD model of antipsychotic effect of CBF measures . Indeed, we were able to show that quantitative measures of brain functional effect of antipsychotics (i.e. CBF changes) are directly associated with receptor density measures. However, intrinsic limitations of the ABA dataset should be considered when evaluating mRNA/ΔCBF relationships. First the number of available ABA donors is limited (N ¼ 6) and therefore only approximates population-level brain mRNA expression templates. However, despite this limitation, ABA data has been showed to be able to predict brain protein densities (Beliveau et al., 2017; Gryglewski et al., 2018; Rizzo et al., 2016 Rizzo et al., , 2014 Veronese et al., 2016) and other neuroimaging measures (Hawrylycz et al., 2015; Richiardi et al., 2015; Ritchie et al., 2018) . Another limitation is that different approaches have been proposed to analyse this dataset (French and Paus, 2015; Gryglewski et al., 2018) . The fact that different strategies in ABA dataset processing could affect reproducibility of the findings is under debate (Arnatkeviciute et al., 2018) . We have also analysed the mRNA/ΔCBF correlations using a different methods that employs whole-brain voxel-wise mRNA expression maps obtained from variograms (Gryglewski et al., 2018) . The results of this analysis were comparable with the analysis performed in MENGA (Supplementary Materials). Therefore we believe that it is unlikely that this methological issue could have biased our results.
Differential strength of association between ΔCBF and receptor density profiles
The correlation strength between ΔCBF and receptor density measured with PET varied between the different antipsychotics tested (Fig. 4) . One possible interpretation of this difference might be related to the differential affinities for these compounds to D 2 R . Our data seems to be in line with this hypothesis. In fact, the strengths of the association were higher for antipsychotics with higher affinity for D 2 R (Table 1 and Fig. S1 ). In particular, HAL was the drug with the highest correlation coefficient and the lowest Ki, whereas OLA showed the lowest correlation coefficient and the highest Ki. Both lowRIS and highRIS were in the middle between HAL and OLA. Another possible interpretation might be that related with the different secondary affinities between the drugs. For instance, for compounds with an high affinity with 5HT2a receptors like risperidone and olanzapine, part of the effect on CBF might also be linked with a mechanism different from D 2 R blockade (Goozee et al., 2014) . In fact, both OLA and RIS as well as other second-generation antipsychotics (e.g. aripiprazole) showed decreases in CBF especially in cortical areas with a mechanism that is possibly mediated by 5HT2a receptors (Handley et al., 2013; Lahti et al., 2005) . We did not find differences in correlations between the two different doses of risperidone, despite the fact that they do show different effect size in CBF increase (as shown in Fig. 2 bottom row) . This might indicate that the coupling between the measurable physiological effects and target receptor distribution can be detected regardless the dose of the compound if that dose is able to produce detectable functional effects. Nonetheless, differences in brain disposition of antipsychotics have been reported in previous studies (Kornhuber et al., 2006; Rodda et al., 2006) . In particular, animal data suggested that antipsychotics (including the ones considered in the present work) show different blood-brain barrier penetration and brain clearance leading to dissimilar spatial distribution in the brain (Loryan et al., 2016) . Even though these dissimilarities have been reported to be only moderate (Loryan et al., 2016 ), brain disposition is a factor to be considered in addition to receptor affinity when linking the pharmacodynamics of each antipsychotic with receptor occupancy. Therefore, without maps of brain deposition variation, conclusions regarding the D 2 R affinities and strength of associations between receptors and CBF are necessarily incomplete. 
Limitations
A number of limitations need to be considered for the present study. First, we used population-based profiles of D 2 R density as the spatial architecture of D 2 R is typically consistent across individuals (Rizzo et al., 2014; Veronese et al., 2016) . For example, the striatum always has higher D 2 R density than the thalamus which in turn has higher D 2 R density than the cortex. However, variance in density between individuals within the same brain region may drive inter-individual differences in the drug functional response. Individualized receptor profiles mapping is therefore necessary to bring more precision to the method and to further validate the present findings. Nevertheless, normative atlases for protein and mRNA expressions have proven useful in many different applications, suggesting that the core spatial architecture of the brain receptor systems is consistent across individuals (Beliveau et al., 2017; Rizzo et al., 2016 Rizzo et al., , 2014 Veronese et al., 2016) .
In addition, we considered only local effects by matching CBF changes and D 2 R receptor density measures with the same ROIs. However, studies in patients and healthy volunteers showed that antipsychotics also produce changes in functional connectivity in rs-fMRI suggesting the existence of downstream effects (Cole et al., 2013; Sarpal et al., 2015) that were not included in our analyses.
As discussed above, increases in CBF after acute antipsychotic challenge have been usually interpreted as the result of a neuronal metabolic changes due to D 2 R blockade. D 2 -like receptors are also present in perivascular astrocytes and endothelial cells modulating brain hemodynamic changes. However these receptors are mainly D 3 R and not D 2 R (Choi et al., 2006) . Together with the knowledge that the affinity of these compounds for D 2 R is higher than for D 3 R we expect the change in CBF is mainly neuronal in origin. In addition, both risperidone and olanzapine, but not haloperidol, act as antagonists at the serotonin-2a receptors (5HT2a) (Meltzer, 1999) . Blockade of 5HT2a receptors on smooth-muscle cells of brain arteries has been shown to induce relative vasodilation in animal models (i.e. blocking vasoconstriction caused by the endogenous ligand serotonin) (Kov acs et al., 2012) . Therefore, the degree to which these non-neuronal effects contribute to the associations described here is not known. Finally, we believe that the limited sample size offered by the ABA (N ¼ 6) could have undermined power in detecting a linear relationship between mRNA data and rCBF changes. This factor could also be an alternative explanation of the difference we found between mRNA and PET correlations with rCBF.
Conclusion
Understanding the link between neurochemical changes and brain function is crucial to uncover mechanisms underlining the effects of psychopharmacological treatment and between-subjects variability in response. In this work we investigated the case of antipsychotics whose functional effect, evaluated as changes in CBF measures, mirror the wellknown spatial distributions of their main target (i.e. D 2 R). The characterisation of the haemodynamic response using this multimodal approach might be applicable also for other classes of drugs and it becomes particularly valuable for profiling compounds known to bind to multiple targets or with unknown or poorly characterised targets. Finally, our work demonstrates that the use of MRI 3D pCASL as a measure of regional CBF offers an efficient, non-invasive tool to investigate CNS penetration in the process of psychotropic drug development that is also linked with brain chemistry.
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